arrow
A

Aaron M. Samuels

US Centers for Disease Control and Prevention
H指数:30
被引数:2,914

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Respiratory Syncytial Virus Symptomatic Fraction, Shedding and Detection in Children Aged 6–23 Months in South Africa in 2022

2022年南非6-23月龄儿童呼吸道合胞病毒症状分数、病毒排出及检测情况

2026-09-020
OAAI
The Malaria Vaccine Programme Evaluation in Kenya: results of a baseline household survey prior to the introduction of the RTS,S/AS01 vaccine

肯尼亚疟疾疫苗项目评估:RTS,S/AS01疫苗引入前的基线家庭调查结果

2026-04-210
PRE
Assessing the impact of temporal changes in transmission on Plasmodium falciparum strains in Asembo, western Kenya (1996-2017) using within-host metrics via 24-SNP barcodes

评估1996-2017年间在肯尼亚西部阿森博地区,通过24-SNP条形码利用宿主体内指标评估传播时间变化对恶性疟原虫菌株的影响

2025-12-170
PRE
Effectiveness of the 2023 Southern Hemisphere Influenza Vaccine Against Outpatient Influenza-Like Illness: A Multi-Country Test-Negative Design Study

2023年南半球流感疫苗对门诊流感样疾病的保护效果:一项多国“阴性对照”设计研究

2025-10-010
OA
Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial

RTS,S/AS01E疟疾疫苗在50个月随访期间,在加纳和肯尼亚的幼儿中使用全剂量或分剂量方案时的持续有效性:一项开放标签、IIb期、随机对照试验的最终结果

2025-09-170
PREAI
A Potential Platform for Future Vaccine Trials Identifies a High Incidence of Symptomatic and Asymptomatic Influenza Infection Among Children Aged 6 to 23 Months in South Africa

未来疫苗试验的潜在平台确定了南非6至23个月儿童中有症状和无症状流感感染的高发病率

2024-11-140
OAAI
Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial
2024-09-013
OAAI
Risk Factors for Severe COVID-19 Among Children and Adolescents Enrolled in Acute Respiratory Infection Sentinel Surveillance in South Africa, 2020-2022
2024-04-260
OAAI
Feasibility, safety, and impact of the RTS,S/AS01 E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi
LANCET
IF88.5
2024-04-015
OAAI
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine

少即是多吗?在评估RTS,S/AS01E疟疾疫苗的接种效果时,如何考虑分次剂量接种方案及不同剂次的疫苗接种数量

2024-03-040
OAAI
Burden of child mortality from malaria in high endemic areas: Results from the CHAMPS network using minimally invasive tissue sampling

疟疾高流行地区儿童死亡率的负担: 使用微创组织采样的CHAMPS网络的结果

2024-03-015
OA
Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data
2022-09-169
OAAI
Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
2022-09-0123
OAAI
Diagnostic Performance of Loop-Mediated Isothermal Amplification and Ultrasensitive Rapid Diagnostic Tests for Malaria Screening Among Pregnant Women in Kenya

环介导等温扩增和超灵敏快速诊断试验在肯尼亚孕妇疟疾筛查中的诊断性能

2022-07-115
OA